Retinoids as Novel Treatment of Ischemic Stroke

Information

  • Research Project
  • 7108051
  • ApplicationId
    7108051
  • Core Project Number
    R41NS053041
  • Full Project Number
    1R41NS053041-01A1
  • Serial Number
    53041
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/2006 - 18 years ago
  • Project End Date
    8/31/2008 - 16 years ago
  • Program Officer Name
    JACOBS, TOM P.
  • Budget Start Date
    9/15/2006 - 18 years ago
  • Budget End Date
    8/31/2008 - 16 years ago
  • Fiscal Year
    2006
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    9/14/2006 - 18 years ago
Organizations

Retinoids as Novel Treatment of Ischemic Stroke

[unreadable] DESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the U.S. and a major source of disability. Ischemic stroke, the most common type, is associated with a dramatic increase in calcium influx in brain tissue, an increased production in reactive oxygen species (ROS), cell death and inflammation. Studies by the PI have shown that retinoids block neuronal voltage-gated calcium channels. Studies by others suggest that retinoids reduce tissue levels of reactive oxygen species and prevents cellular apoptosis, increase tissue plasminogen activator, favorably modify the balance of pro-inflammatory and inflammatory cytokines and attenuate inflammation in vivo. Together, the data suggest that retinoids might be neuroprotective and potentially useful in the treatment of ischemic stroke. Our goal is to demonstrate that retinoids have neuroprotective activity in vivo. Specifically, we propose to demonstrate that treatment with retinoids: 1) attenuates post-stroke motor deficits using a mouse model of permanent focal cerebral ischemia (middle cerebral artery occlusion), 2) reduces cerebral infarct size, and 3) reduces the expression of the biochemical markers of apoptosis, ROS production and inflammation in the ischemic brain. The project will provide a rationale for the development of retinoid-based formulations to treat ischemic stroke and for the screening of retinoid libraries in search of more potent compounds. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R41
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    130453
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:130453\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ACRYMED, INC.
  • Organization Department
  • Organization DUNS
    878062256
  • Organization City
    BEAVERTON
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    97008
  • Organization District
    UNITED STATES